Description
Anti-Human TNF Therapeutic Antibody (Adalimumab) (CAT#: TAB-010)
Recombinant monoclonal antibody to Respiratory syncytial virus TNF. Adalimumab (HUMIRA, AbbVie) is the third TNF inhibitor, after infliximab and etanercept. Like infliximab and etanercept, adalimumab binds to Tumor necrosis factor-alpha (TNFa), preventing it from activating TNF receptors. Adalimumab was constructed from a fully human monoclonal antibody, while infliximab is a mouse-human chimeric antibody and etanercept is a TNF receptor-IgG fusion protein. TNFa inactivation has proven to be important in downregulating the inflammatory reactions associated with autoimmune diseases. adalimumab is for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis. Although only approved for ulcerative colitis from late 2012 by the FDA in the disease's management, it has been used for several years in cases that have not responded to conventional treatment at standard dosing for Crohn's Disease.
Tumor necrosis factor (TNF, cachexin, or cachectin; once named as tumor necrosis factor alpha or TNFa) is a cell signaling protein (cytokine) involved in systemic inflammation and is one of the cytokines that make up the acute phase reaction. It is produced chiefly by activated macrophages, although it can be produced by many other cell types such as CD4+ lymphocytes, NK cells, neutrophils, mast cells, eosinophils, and neurons. TNF is a member of the TNF superfamily, consisting of various transmembrane proteins with a homologous TNF domain. The primary role of TNF is in the regulation of immune cells. TNF, being an endogenous pyrogen, is able to induce fever, apoptotic cell death, cachexia, inflammation and to inhibit tumorigenesis and viral replication and respond to sepsis via IL1- & IL6-producing cells. Dysregulation of TNF production has been implicated in a variety of human diseases including Alzheimer's disease,[6] cancer, major depression, psoriasis and inflammatory bowel disease (IBD).
Creative Biolabs is a leader of recombinant antibody (rAb) discovery and manufacturing, providing high quality service to customers in academia and industry fields all over the world.
Our cutting-edge hybridoma development and phage display platforms allow the production of the most comprehensive list of recombinant antibody products and extensive service portfolio at the most competitive price. Our products range from antibody / peptide libraries, Biosimilar cell lines, Chimeric antigen receptor (CAR) products, antibody-drug conjugates (ADCs) to engineered antibodies such as therapeutic antibodies, single-domain antibodies, bispecific antibodies and intrabodies. We also provide professional custom antibody discovery and engineering services, featuring phage display library construction, antibody humanization, chimerization, engineered antibody production (Fab, scFc, tribody, bispecific antibody, SdAb, minibody, etc.), antibody labeling, hybridoma/stable cell line development, membrane protein production and cGMP-manufacturing which enable larger scale antibody production for development of animal-based assays and clinical trials.